Search

Displaying results 2901 - 2910 of 7063 in total
  1. Drug

    Etarotene

    go.drugbank.com/drugs/DB21071
    Experimental

    Etarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Etarotene is a arotinoid derivative. Etarotene has a monoisotopic molecular weight of 396.21 Da.

  2. Drug

    Pinolcaine

    go.drugbank.com/drugs/DB21159
    Experimental

    Pinolcaine is a small molecule drug. The usage of the INN stem '-caine' in the name indicates that Pinolcaine is a local anaesthetic. Pinolcaine has a monoisotopic molecular weight of 351.22 Da.

  3. Drug

    Lorcinadol

    go.drugbank.com/drugs/DB21160
    Experimental

    Lorcinadol is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Lorcinadol is a analgesic. Lorcinadol has a monoisotopic molecular weight of 314.13 Da.

  4. Drug

    Linarotene

    go.drugbank.com/drugs/DB21165
    Experimental

    Linarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Linarotene is a arotinoid derivative. Linarotene has a monoisotopic molecular weight of 398.2 Da.

  5. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

  6. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  7. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

  8. Drug

    Chromium gluconate

    go.drugbank.com/drugs/DB14528
    Approved

  9. Drug

    Chromium nicotinate

    go.drugbank.com/drugs/DB14529
    Approved

  10. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    have a history of vaso-occlusive events. … Specifically, lovotibeglogene autotemcel provides a functional copy of a modified beta-globin gene (β<sup>A-T87Q</sup>-globin) that when combined with α-globin, produces hemoglobins with similar oxygen-binding